Fintel reports that on January 22, 2025, Stifel initiated coverage of Edgewise Therapeutics (NasdaqGS:EWTX) with a Hold ...

BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company's focus ...

Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the ...

Paul Matteis, an analyst from Stifel Nicolaus, has initiated a new Hold rating on Edgewise Therapeutics (EWTX).Invest with Confidence: Follow ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during ...

So notwithstanding the buoyant share price, we think it's well worth asking whether Edgewise Therapeutics' cash burn is too risky. In this report, we will consider the company's annual negative free ...

Check the time stamp on this data. Updated AI-Generated Signals for Edgewise Therapeutics Inc. (EWTX) available here: EWTX.

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent ...

On Friday, Evercore ISI initiated coverage on Edgewise Therapeutics (NASDAQ:EWTX) shares, a biopharmaceutical company, with an Outperform rating and a price target of ...